盐城地区食管癌化疗患者近期生命质量评价

doi:10.3969/j.issn.1004-616x.2017.06.007

癌变·畸变·突变 ›› 2017, Vol. 29 ›› Issue (6): 437-444,449.doi: 10.3969/j.issn.1004-616x.2017.06.007

盐城地区食管癌化疗患者近期生命质量评价

何曙芝^1,2, 赵跃¹, 刘洋¹, 杨留才¹, 陈平³, 刘冉⁴

1. 江苏医药职业学院, 江苏盐城 224001;
2. 盐城市妇幼保健院, 江苏盐城 224001;
3. 盐城市第一人民医院, 江苏盐城 224001;
4. 环境医学工程教育部重点实验室, 东南大学公共卫生学院, 江苏南京 210009

收稿日期:2017-08-22 修回日期:2017-10-24 出版日期:2017-11-30 发布日期:2017-11-30
通讯作者: 刘冉,E-mail:ranliu@seu.edu.cn E-mail:ranliu@seu.edu.cn
作者简介:何曙芝,E-mail:yc_hsz@126.com。
基金资助:
国家自然科学基金项目（81573108）；盐城市医学科技发展计划项目（YK2013051）

Evaluation of the quality of life among esophageal cancer patients who received chemotherapy

HE Shuzhi^1,2, ZHAO Yue¹, LIU Yang¹, YANG Liucai¹, CHEN Ping³, LIU Ran⁴

1. Jiangsu Vocational College of Medicine, Yancheng 224001;
2. Yancheng Maternity and Child Health Care Hospital, Yancheng 224001;
3. Yancheng City No.1 Peoples Hospital, Yancheng 224001;
4. Key Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing 210009, Jiangsu, China

Received:2017-08-22 Revised:2017-10-24 Online:2017-11-30 Published:2017-11-30

摘要/Abstract

摘要： 目的：通过对盐城地区中晚期食管癌化疗患者近期生命质量（QOL）进行评价，指导临床化疗方案的选择及提高患者生命质量。方法：收集2013-2014年49例原发性食管癌新发病例在化疗前1 d、化疗后1周、化疗后4周的人口学资料、疾病与治疗情况、生命质量测量量表，运用癌症患者生命质量核心量表（EORTC QLQ-C30）按5个功能领域、3个症状领域、6个单项测量条目及1个总体健康状况领域将生命质量测量分值进行标准化换算。对人口学资料及疾病特征、患者化疗前后QOL的变化、影响化疗患者QOL的因素采用SPSS 17.0软件进行统计描述和分析。结果：化疗后1周较化疗前1 d功能领域有所改善，但恶心呕吐、疼痛、失眠、腹泻症状及经济困难加重（P < 0.05）；化疗后4周较化疗前1 d除社会支持功能外，功能领域得分变高，躯体症状加重（P < 0.05）；化疗后4周较化疗后1周躯体、角色、总体功能改善（P < 0.05），但恶心呕吐、食欲丧失、腹泻仍有加重现象（P < 0.05）。QOL与年龄、文化程度、居住地、临床分期、不同淋巴转移结局有关。结论：化疗患者生命质量受化疗时间、年龄和文化程度等相关因素的影响，需通过选择个性化方案、采取综合措施来提高。

关键词: 食管癌, 化疗, 生命质量, 评价

Abstract: OBJECTIVE:To assess the quality of life of advanced esophageal cancer patients who received chemotherapy in the Yancheng area,China and to guide the choice of clinical chemotherapy regimens. METHODS:Data on demographic information,disease and treatment,quality of life scale and EORTC QOL-C30 scale were collected from 49 new primary esophageal cancer cases undergoing chemotherapy. Data were collected at one day before chemotherapy and one week,four weeks after chemotherapy. According to five functional areas and three semiotic areas including six single measurement items,and one general health area,scores of QOL were changed into standard measure to analyze demographic data,disease characteristic,patients' QOL before and after chemotherapy and factors influencing patients' QOL undergoing chemotherapy. Software 17.0 was applied to describe and to analyze data including demographic data,disease characteristic,patients' QOL before and after chemotherapy and factors influencing patients' QOL undergoing chemotherapy. RESULTS:Compared with one day before chemotherapy,function score improved one week after chemotherapy. But symptoms of vomit and nausea,pain,insomnia,diarrhea and financial difficulty got worse in general after chemotherapy(P < 0.05). Except social support function,function score increased,and somatic symptoms aggravated more significantly 4 weeks after chemotherapy than that of one day before chemotherapy(P < 0.05). Compared with one week after chemotherapy,physical,role and overall functions improved 4 weeks after chemotherapy(P < 0.05). But symptoms of vomit and nausea,loss of appetite and diarrhea got worse (P < 0.05). Quality of life was related to age,educational level,residence clinical stage,and different routes of metastasis. CONCLUSION:Patients' quality of life after undergoing chemotherapy was affected by duration of chemotherapy,age and educational level,which can be improved by selecting individual scheme and adopting comprehensive management.

Key words: esophageal cancer, chemotherapy, quality of life, evaluation

中图分类号:

R735.1

何曙芝, 赵跃, 刘洋, 杨留才, 陈平, 刘冉. 盐城地区食管癌化疗患者近期生命质量评价[J]. 癌变·畸变·突变, 2017, 29(6): 437-444,449.

HE Shuzhi, ZHAO Yue, LIU Yang, YANG Liucai, CHEN Ping, LIU Ran. Evaluation of the quality of life among esophageal cancer patients who received chemotherapy[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(6): 437-444,449.

参考文献

[1] 庹吉好,魏少忠,李广灿,等. 湖北省不同地区食管/贲门癌(上消化道癌)早诊早治效果分析[J]. 中国肿瘤,2015,24(8):653-656.
[2] 丁颖,苏琼菲,杨帆,等. 食管癌术前同步多西他赛联合顺铂化放疗的临床观察[J]. 中华肿瘤防治杂志,2012,19(9):679-682.
[3] 孙晓凯,刘荣海,周文君. 盐城市居民食管癌死亡趋势及Joinpoint回归分析[J]. 现代预防医学,2010,37(14):2620-2622.
[4] 丁金霞,王婷,王维利,等. 化疗期癌症患者癌因性疲乏与生命质量的研究[J]. 中华疾病控制杂志,2015,19(5):462-465.
[5] AARONSON N K,MEYEROWITZ B E,BARD M,et al. Quality of life research in oncology. past achievements and future priorities[J]. Cancer,1991,67(Sup 3):839-843.
[6] 方积乾. 生存质量测定方法及应用[M]. 北京:北京医科大学出版社,2001:263-267.
[7] SCARPA M,SAAEEH L M,FASOB A,et al. Healthy-related quality of life in patients with oesophageal cancer:analysis at different steps of the treatment path way[J]. J Gastrointest Surg,2013,17(3):421-433.
[8] 王俊,王丽丹,江启成. 我国肿瘤患者生命质量评价研究现状及特点[J]. 中华疾病控制杂志,2017,21(4):422-424.
[9] 钱勇,潘跃银,孙国平,等. 食管癌新辅助化疗患者生活质量的定量研究[J]. 肿瘤研究与临床,2006,18(4):233-236.
[10] 罗利民,贾勇士,吴树强. 卡培他滨联合放疗对老年食管癌患者的治疗效果及生活质量的影响[J]. 中国老年学杂志,2016,36(1):103-105.
[11] 孙佳春,王新帅,刘刚,等. XELOX化疗方案对老年晚期食管癌患者生存质量的影响[J]. 中国老年学杂志,2012,32(22):4915-4916.
[12] 韩振坤,王新帅,王婧婧,等. DCF方案化疗对中晚期食管癌患者生活质量影响的研究[J]. 吉林医学,2011,32(13):2538-2540.
[13] 陈秀芳,李刚,张薛榜,等. 同步放化疗治疗与手术治疗对食管癌患者生活质量影响的比较分析[J]. 温州医学院学报,2013,43(6):371-374.
[14] FAYERS P M,ASRONSON N K,BJORDAL K,et al. On Behalf of the EORTC Quality of Life Study Group. The EORTC QOL-C30 Scoring Manual[M]. 3rd ed. Brussels:EORTC,2001:6-7.
[15] 薛永生,任国琴,涂小妹. 食管癌患者住院生活质量自评量表编制与检验[J]. 中外医学研究,2009,7(13):46-48.
[16] 施朕善,蒋祥德. 生存质量在食管癌中的研究现状[J]. 现代肿瘤医学,2015,23(5):723-726.
[17] 张林,马伟,李云,等. 不同术式对老年食管癌切除术后患者生活质量的影响[J]. 中国老年学杂志,2013,33(20):5017-5018.
[18] LAZEBY J M B,WILLIANS M H,BROOKES S T,et al. Quality of life measurement in patients with oesophageal cancer[J]. Gut,1995,37(4):505-508.
[19] 吴伟英,林白浪,林桦,等. 知信行模式健康教育对食管癌患者健康行为及生存质量的影响[J]. 中国健康教育,2016,32(5):455-461.
[20] 李向青,李荣,任利华,等. 社会支持对食管癌手术后患者生命质量的影响[J]. 现代预防医学,2012,39(13):3314-3315,3317.
[21] 鲁勇国,梅波,万志渝,等. 胸腔镜食管癌切除术后患者近期生命质量的评价[J]. 中国胸心血管外科临床杂志,2016,23(3):248-252.
[22] 李宁. 同期放化疗对食管癌患者近期生存质量的影响[J]. 临床医学,2016,36(8):72-73.
[23] 徐洪波,江浩,张亚军,等. 三维适形放疗联合奥沙利铂加卡培他滨同步化疗治疗Ⅲ期食管癌的疗效[J]. 中国老年学杂志,2015,35(19):5522-5524.
[24] 孙燕. 内科肿瘤学[M]. 北京:人民卫生出版社,2001:534.
[25] 周际昌. 实用肿瘤内科学[M]. 北京:人民卫生出版社,2003:572-588.
[26] 梁青梅,张萍. 食管癌晚期患者临终关怀的护理体会[J]. 基层医学论坛,2010,14(27):827.
[27] 吴天亮. 食管癌量表QLICP-ES的评价及食管癌患者生命质量的分析[D]. 泰安:泰山医学院,2014.
[28] HJERMSTAD M J,FAYERS P M,BJORDAL K,et al. Health related quality of life in the general Norwegian Population assessed by the European organization for research and treatment of cancer core quality of life questionnaire:the QLQ-C30[J]. J Clin Oncol,1998,16(3):1188-1196.
[29] BLAZEBY J M,BROOKES S T,ALDERSON D. Prognostic value of quality of life scores in patients with esophageal cancer[J]. Br J Surg,2000,87(3):362-373.
[30] MIEHELSON H,BLOUND C,NILSSON B,et al. Health-related quality of life measured by the EORTC QLQ-C30 reference values from a large sample of Swedish population[J]. Aetaoneol,2000,39(4):477-484.
[31] BOUCHARDY C,FIORETTAG,D E PERROT M,et al. Determinants of long term survival after survival after surgery for cancer of the lung:A population-based study[J]. Cancer,1999,86(11):2229-2237.
[32] 马红霞,刘艳,罗红格,等. 癌症患者生命质量状况调查及其影响因素分析[J]. 中国健康心理学杂志,2012,20(5):667-668.

盐城地区食管癌化疗患者近期生命质量评价

Evaluation of the quality of life among esophageal cancer patients who received chemotherapy

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	问天娇, 李思颖, 郑颖, 崔京霞. 脂质体技术在铂类药物抗肿瘤研究中的应用[J]. 癌变·畸变·突变, 2022, 34(1): 72-74.
[2]	蔡绮, 高德煜, 史建峰, 于浩, 韩妍, 杨柳, 赵蕾, 王召旭. 以树鼩为微核试验新型动物模型的初步研究[J]. 癌变·畸变·突变, 2021, 33(5): 370-374,382.
[3]	马亚南, 吴楠, 金焰. 肿瘤微环境与卵巢癌化疗耐药机制的研究进展[J]. 癌变·畸变·突变, 2021, 33(5): 393-395,400.
[4]	刘强强, 李宏霞, 肖凯. 纳米材料生物安全性的影响因素与评价方法[J]. 癌变·畸变·突变, 2021, 33(4): 321-325.
[5]	张玉铃, 吴俊东, 潘东岳, 陈春发. 乳腺癌新辅助化疗前后Ki67变化对疗效及预后的意义[J]. 癌变·畸变·突变, 2021, 33(3): 230-235,245.
[6]	张玉领, 陈培. 环状RNA在食管癌中的研究进展[J]. 癌变·畸变·突变, 2021, 33(3): 241-245.
[7]	张娜, 范志露, 杨荔艳, 常晨, 蔡岩, 郝佳洁, 王明荣. 食管鳞癌中SERPINB5表达降低的作用机制及其临床意义[J]. 癌变·畸变·突变, 2021, 33(2): 101-109.
[8]	焦文静, 郭秀娟, 马鸣, 邵俊国, 张金艳. 老年局部晚期食管癌同步放化疗与单纯放疗的疗效比较[J]. 癌变·畸变·突变, 2021, 33(2): 124-128.
[9]	陈婉娴, 王思梦, 陈张瑜, 王潘集, 郑淳文, 李恩民, 许丽艳. CDC42抑制剂CASIN对食管癌细胞活力与迁移能力的抑制作用[J]. 癌变·畸变·突变, 2021, 33(2): 136-142.
[10]	杨丽, 张孟贤, 张微, 熊英友, 陈世勇, 方呈祥. 基于数据挖掘分析极光激酶A在食管癌中的表达及意义[J]. 癌变·畸变·突变, 2020, 32(3): 221-228.
[11]	熊英友, 杨丽, 方呈祥, 吴倩, 张微, 赵毅, 文静. 数据挖掘分析SLC7A11在食管癌中的表达及通过P53/ROS通路调节细胞铁死亡的意义[J]. 癌变·畸变·突变, 2020, 32(2): 126-131.
[12]	封敏, 艾比拜·莫合塔尔, 石静怡, 祖可来·艾力江, 李永祥, 闫长顺, 李秀梅. 哈萨克族食管癌组织中miR-143、miR-145和Survivin mRNA的表达及其临床病理意义[J]. 癌变·畸变·突变, 2020, 32(1): 29-32.
[13]	马莉莉, 张树丽, 李琴, 许彭, 封敏, 李秀梅. 新疆哈萨克族食管癌与正常组织间差异表达miRNA的筛查及验证[J]. 癌变·畸变·突变, 2020, 32(1): 52-56.
[14]	王荀, 李斌, 刘俩燕, 杨敏, 邹宇量. 深圳市龙岗区饮用水中常规指标的健康风险评价[J]. 癌变·畸变·突变, 2019, 31(5): 359-362.
[15]	万树泉, 魏丽军, 王福花, 曾勇. miR-200b-3p和PAK2 mRNA在耐药卵巢癌组织中的表达及其临床意义[J]. 癌变·畸变·突变, 2019, 31(3): 216-221.